Klygefa (gefurulimab-gaks) was approved by the FDA on November 13, 2026 to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, the 50th novel drug approval of 2026 on the FDA's Novel Drug Approvals list.
Verified against: FDA action day November 13, 2026 (BLA 761488 ORIG-1 (FDA letter)) · Announcement November 16, 2026 · Goal date: none on record.
This page was first committed to pdufa.bio's public repository on Nov 21, 2026, 9:14 AM ET (public commit 012d17f). Dates on this page are the FDA's and the sponsor's; this line is ours.
The FDA's approval letter for BLA 761488, signed November 13, 2026 (FDA letter), covers Klygefa (gefurulimab-gaks) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor (AChR) antibody positive. The letter states that the application was received on November 13, 2025, and it approves a REMS because of the risk of serious meningococcal infections. AstraZeneca announced the approval on November 16, 2026 and describes once-weekly subcutaneous self-administration by autoinjector (AstraZeneca, November 16, 2026). Per AstraZeneca, in the Phase III PREVAIL trial (260 patients) the MG-ADL total score improved more than with placebo at week 26 (treatment difference -1.6, p<0.0001). We hold no publicly disclosed PDUFA goal date for this application, so no early or late margin is given.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
Primary source: FDA approval letter, BLA 761488, November 13, 2026
FDA record of the action: the FDA approved on November 13, 2026, per BLA 761488 ORIG-1 (FDA letter). The sponsor announced it on November 16, 2026. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| OrbiMed Advisors | 379,300 | $61.8 million | filed November 16, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Yes. The FDA approved the application for Klygefa (gefurulimab-gaks) on November 13, 2026, per the FDA's own record. The company announced it on November 16, 2026. The primary source is linked on this page.
Klygefa (gefurulimab-gaks) is an AstraZeneca PLC (Alexion) (AZN) program. The FDA decision came on November 13, 2026; the FDA's own record of the decision is linked on this page.
AZN moved -0.2%, measured as the 2026-11-16 close (the announcement day) against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
Yes. The FDA approved Klygefa (gefurulimab-gaks) on November 13, 2026 for adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive (BLA 761488). AstraZeneca announced it on November 16, 2026.
Per AstraZeneca, Klygefa is self-administered under the skin once a week with an autoinjector. The FDA letter approves a REMS because of the risk of serious meningococcal infections.
pdufa.bio holds no publicly disclosed PDUFA goal date for this application, so no margin is given. The FDA letter states that the application was received on November 13, 2025.